MYD88 and serum lipopolysaccharide activity: This dual protection aligns with reports that DIO suppresses the TLR4-MyD88-NF-κB axis (Jin et al., 2022), thereby reducing endotoxemia and interrupting the vicious cycle of gut-derived inflammation and renal injury.